Update on FGF23 and Klotho signaling

Molecular and Cellular Endocrinology

Volumn 432, Issue , 2016, Pages 56-65

  Erben, Reinhold G ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Bone; FGF23; Fibroblast growth factor 23; Kidney; Klotho; Parathyroid gland

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; GLYCOSIDASE; KLOTHO PROTEIN; RECEPTOR; BETA GLUCURONIDASE; FIBROBLAST GROWTH FACTOR;

ARTICLE; AUTOCRINE EFFECT; BONE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; ENDOCRINE FUNCTION; ENZYME ACTIVITY; HORMONE ACTION; HUMAN; KIDNEY; MINERAL METABOLISM; NONHUMAN; PARACRINE SIGNALING; PARATHYROID GLAND; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MODELS, BIOLOGICAL; ORGAN SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84969262871     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2016.05.008     Document Type: Article

References (121)

1. Andrukhova, O., Zeitz, U., Goetz, R., Mohammadi, M., Lanske, B., Erben, R.G., FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway. Bone 51 (2012), 621–628.
2. Andrukhova, O., Slavic, S., Smorodchenko, A., Zeitz, U., Shalhoub, V., Lanske, B., Pohl, E.E., Erben, R.G., FGF23 regulates renal sodium handling and blood pressure. EMBO Mol. Med. 6 (2014), 744–759.
3. Andrukhova, O., Slavic, S., Zeitz, U., Riesen, S.C., Heppelmann, M.S., Ambrisko, T.D., Markovic, M., Kuebler, W.M., Erben, R.G., Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice. Mol. Endocrinol. 28 (2014), 53–64.
4. Andrukhova, O., Smorodchenko, A., Egerbacher, M., Streicher, C., Zeitz, U., Goetz, R., Shalhoub, V., Mohammadi, M., Pohl, E.E., Lanske, B., Erben, R.G., FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J. 33 (2014), 229–246.
5. Andrukhova, O., Slavic, S., Odorfer, K.I., Erben, R.G., Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J. Bone Min. Res. 30 (2015), 1831–1839.
6. Anour, R., Andrukhova, O., Ritter, E., Zeitz, U., Erben, R.G., Klotho lacks a vitamin D independent physiological role in glucose homeostasis, bone turnover, and steady-state PTH secretion in vivo. PLoS One, 7, 2012, e31376.
7. Araya, K., Fukumoto, S., Backenroth, R., Takeuchi, Y., Nakayama, K., Ito, N., Yoshii, N., Yamazaki, Y., Yamashita, T., Silver, J., Igarashi, T., Fujita, T., A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J. Clin. Endocrinol. Metab. 90 (2005), 5523–5527.
8. Bazua-Valenti, S., Gamba, G., Revisiting the NaCl cotransporter regulation by with No-lysine kinases. Am. J. Physiol. Cell Physiol. 308 (2015), C779–C791.
9. Ben Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-O, M., Mohammadi, M., Sirkis, R., Naveh-Many, T., Silver, J., The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest 117 (2007), 4003–4008.
10. Bergwitz, C., Roslin, N.M., Tieder, M., Loredo-Osti, J.C., Bastepe, M., Abu-Zahra, H., Frappier, D., Burkett, K., Carpenter, T.O., Anderson, D., Garabedian, M., Sermet, I., Fujiwara, T.M., Morgan, K., Tenenhouse, H.S., Juppner, H., SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am. J. Hum. Genet. 78 (2006), 179–192.
11. Bhadada, S.K., Palnitkar, S., Qiu, S., Parikh, N., Talpos, G.B., Rao, S.D., Deliberate total parathyroidectomy: a potentially novel therapy for tumor-induced hypophosphatemic osteomalacia. J. Clin. Endocrinol. Metab. 98 (2013), 4273–4278.
12. Brandenburg, V.M., Kleber, M.E., Vervloet, M.G., Tomaschitz, A., Pilz, S., Stojakovic, T., Delgado, G., Grammer, T.B., Marx, N., Marz, W., Scharnagl, H., Fibroblast growth factor 23 (FGF23) and mortality: the ludwigshafen risk and cardiovascular health Study. Atherosclerosis 237 (2014), 53–59.
13. Brandenburg, V.M., Kleber, M.E., Vervloet, M.G., Larsson, T.E., Tomaschitz, A., Pilz, S., Stojakovic, T., Delgado, G., Grammer, T.B., Marx, N., Marz, W., Scharnagl, H., Soluble klotho and mortality: the ludwigshafen risk and cardiovascular health study. Atherosclerosis 242 (2015), 483–489.
14. Brownstein, C.A., Adler, F., Nelson-Williams, C., Iijima, J., Li, P., Imura, A., Nabeshima, Y., Reyes-Mugica, M., Carpenter, T.O., Lifton, R.P., A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3455–3460.
15. Canalejo, R., Canalejo, A., Martinez-Moreno, J.M., Rodriguez-Ortiz, M.E., Estepa, J.C., Mendoza, F.J., Munoz-Castaneda, J.R., Shalhoub, V., Almaden, Y., Rodriguez, M., FGF23 fails to inhibit uremic parathyroid glands. J. Am. Soc. Nephrol. 21 (2010), 1125–1135.
16. Cha, S.K., Huang, C.L., WNK4 kinase stimulates caveola-mediated endocytosis of TRPV5 amplifying the dynamic range of regulation of the channel by protein kinase C. J. Biol. Chem. 285 (2010), 6604–6611.
17. Cha, S.K., Ortega, B., Kurosu, H., Rosenblatt, K.P., Kuro, O., Huang, C.L., Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9805–9810.
18. Chang, Q., Hoefs, S., Van Der Kemp, A.W., Topala, C.N., Bindels, R.J., Hoenderop, J.G., The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310 (2005), 490–493.
19. Chen, S.Y., Bhargava, A., Mastroberardino, L., Meijer, O.C., Wang, J., Buse, P., Firestone, G.L., Verrey, F., Pearce, D., Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 2514–2519.
20. Clinkenbeard, E.L., Cass, T.A., Ni, P., Hum, J.M., Bellido, T., Allen, M.R., White, K.E., Conditional deletion of murine Fgf23: interruption of the normal skeletal responses to phosphate challenge and rescue of genetic hypophosphatemia. J. Bone Min. Res., 2016 (in press).
21. David, V., Martin, A., Isakova, T., Spaulding, C., Qi, L., Ramirez, V., Zumbrennen-Bullough, K.B., Sun, C.C., Lin, H.Y., Babitt, J.L., Wolf, M., Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89 (2016), 135–146.
22. Deliot, N., Hernando, N., Horst-Liu, Z., Gisler, S.M., Capuano, P., Wagner, C.A., Bacic, D., O'Brien, S., Biber, J., Murer, H., Parathyroid hormone treatment induces dissociation of type IIa Na+-P(i) cotransporter-Na+/H+ exchanger regulatory factor-1 complexes. Am. J. Physiol. Cell Physiol. 289 (2005), C159–C167.
23. Dhingra, R., Sullivan, L.M., Fox, C.S., Wang, T.J., D'Agostino, R.B. Sr., Gaziano, J.M., Vasan, R.S., Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 167 (2007), 879–885.
24. Di Lullo, L., Gorini, A., Bellasi, A., Morrone, L.F., Rivera, R., Russo, L., Santoboni, A., Russo, D., Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. Clin. Kidney J. 8 (2015), 732–736.
25. Dubal, D.B., Yokoyama, J.S., Zhu, L., Broestl, L., Worden, K., Wang, D., Sturm, V.E., Kim, D., Klein, E., Yu, G.Q., Ho, K., Eilertson, K.E., Yu, L., Kuro-o, M., De Jager, P.L., Coppola, G., Small, G.W., Bennett, D.A., Kramer, J.H., Abraham, C.R., Miller, B.L., Mucke, L., Life extension factor klotho enhances cognition. Cell Rep. 7 (2014), 1065–1076.
26. Dubal, D.B., Zhu, L., Sanchez, P.E., Worden, K., Broestl, L., Johnson, E., Ho, K., Yu, G.Q., Kim, D., Betourne, A., Kuro, O., Masliah, E., Abraham, C.R., Mucke, L., Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J. Neurosci. 35 (2015), 2358–2371.
27. Farrow, E.G., Davis, S.I., Summers, L.J., White, K.E., Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 20 (2009), 955–960.
28. Farrow, E.G., Summers, L.J., Schiavi, S.C., McCormick, J.A., Ellison, D.H., White, K.E., Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J. Endocrinol. 207 (2010), 67–75.
29. Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., Gutierrez, O.M., Aguillon-Prada, R., Lincoln, J., Hare, J.M., Mundel, P., Morales, A., Scialla, J., Fischer, M., Soliman, E.Z., Chen, J., Go, A.S., Rosas, S.E., Nessel, L., Townsend, R.R., Feldman, H.I., St John, S.M., Ojo, A., Gadegbeku, C., Di Marco, G.S., Reuter, S., Kentrup, D., Tiemann, K., Brand, M., Hill, J.A., Moe, O.W., Kuro, O., Kusek, J.W., Keane, M.G., Wolf, M., FGF23 induces left ventricular hypertrophy. J. Clin. Invest 121 (2011), 4393–4408.
30. Galitzer, H., Ben Dov, I.Z., Silver, J., Naveh-Many, T., Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77 (2010), 211–218.
31. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M.L., Goetz, R., Mohammadi, M., Baum, M., FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Ren. Physiol. 297 (2009), F282–F291.
32. Gattineni, J., Alphonse, P., Zhang, Q., Mathews, N., Bates, C.M., Baum, M., Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4. Am. J. Physiol. Ren. Physiol. 306 (2014), F351–F358.
33. Geller, J.L., Khosravi, A., Kelly, M.H., Riminucci, M., Adams, J.S., Collins, M.T., Cinacalcet in the management of tumor-induced osteomalacia. J. Bone Min. Res. 22 (2007), 931–937.
34. Goetz, R., Ohnishi, M., Kir, S., Kurosu, H., Wang, L., Pastor, J., Ma, J., Gai, W., Kuro-o, M., Razzaque, M.S., Mohammadi, M., Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 287 (2012), 29134–29146.
35. Grabner, A., Amaral, A.P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., Li, J., Shehadeh, L.A., Hare, J.M., David, V., Martin, A., Fornoni, A., Di Marco, G.S., Kentrup, D., Reuter, S., Mayer, A.B., Pavenstadt, H., Stypmann, J., Kuhn, C., Hille, S., Frey, N., Leifheit-Nestler, M., Richter, B., Haffner, D., Abraham, R., Bange, J., Sperl, B., Ullrich, A., Brand, M., Wolf, M., Faul, C., Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22 (2015), 1020–1032.
36. Gupta, A., Winer, K., Econs, M.J., Marx, S.J., Collins, M.T., FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89 (2004), 4489–4492.
37. Han, X., Yang, J., Li, L., Huang, J., King, G., Quarles, L.D., Conditional deletion of Fgfr1 in the proximal and distal tubule identifies distinct roles in phosphate and calcium transport. PLoS One, 11, 2016, e0147845.
38. Hesse, M., Frohlich, L.F., Zeitz, U., Lanske, B., Erben, R.G., Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 26 (2007), 75–84.
39. Hu, M.C., Shi, M., Zhang, J., Pastor, J., Nakatani, T., Lanske, B., Razzaque, M.S., Rosenblatt, K.P., Baum, M.G., Kuro-o, M., Moe, O.W., Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 24 (2010), 3438–3450.
40. Hu, M.C., Shi, M., Zhang, J., Quinones, H., Griffith, C., Kuro-o, M., Moe, O.W., Klotho deficiency causes vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 22 (2011), 124–136.
41. Ichikawa, S., Imel, E.A., Kreiter, M.L., Yu, X., Mackenzie, D.S., Sorenson, A.H., Goetz, R., Mohammadi, M., White, K.E., Econs, M.J., A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest 117 (2007), 2684–2691.
42. Ichikawa, S., Sorenson, A.H., Austin, A.M., Mackenzie, D.S., Fritz, T.A., Moh, A., Hui, S.L., Econs, M.J., Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 150 (2009), 2543–2550.
43. Imura, A., Tsuji, Y., Murata, M., Maeda, R., Kubota, K., Iwano, A., Obuse, C., Togashi, K., Tominaga, M., Kita, N., Tomiyama, K., Iijima, J., Nabeshima, Y., Fujioka, M., Asato, R., Tanaka, S., Kojima, K., Ito, J., Nozaki, K., Hashimoto, N., Ito, T., Nishio, T., Uchiyama, T., Fujimori, T., Nabeshima, Y., Alpha-Klotho as a regulator of calcium homeostasis. Science 316 (2007), 1615–1618.
44. Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A.H., Scialla, J., Wahl, P., Gutierrez, O.M., Steigerwalt, S., He, J., Schwartz, S., Lo, J., Ojo, A., Sondheimer, J., Hsu, C.Y., Lash, J., Leonard, M., Kusek, J.W., Feldman, H.I., Wolf, M., Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
45. Ito, N., Wijenayaka, A.R., Prideaux, M., Kogawa, M., Ormsby, R.T., Evdokiou, A., Bonewald, L.F., Findlay, D.M., Atkins, G.J., Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol. Cell Endocrinol. 399 (2015), 208–218.
46. Jiang, Y., Ferguson, W.B., Peng, J.B., WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4. Am. J. Physiol. Ren. Physiol. 292 (2007), F545–F554.
47. Jiang, Y., Cong, P., Williams, S.R., Zhang, W., Na, T., Ma, H.P., Peng, J.B., WNK4 regulates the secretory pathway via which TRPV5 is targeted to the plasma membrane. Biochem. Biophys. Res. Commun. 375 (2008), 225–229.
48. Jimbo, R., Kawakami-Mori, F., Mu, S., Hirohama, D., Majtan, B., Shimizu, Y., Yatomi, Y., Fukumoto, S., Fujita, T., Shimosawa, T., Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85 (2014), 1103–1111.
49. Juppner, H., Phosphate and FGF-23. Kidney Int.(Suppl.), 2011, S24–S27.
50. Juppner, H., Wolf, M., Salusky, I.B., FGF-23: more than a regulator of renal phosphate handling?. J. Bone Min. Res. 25 (2010), 2091–2097.
51. Kaneko, I., Saini, R.K., Griffin, K.P., Whitfield, G.K., Haussler, M.R., Jurutka, P.W., FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes. J. Endocrinol. 226 (2015), 155–166.
52. Kato, K., Jeanneau, C., Tarp, M.A., Benet-Pages, A., Lorenz-Depiereux, B., Bennett, E.P., Mandel, U., Strom, T.M., Clausen, H., Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 281 (2006), 18370–18377.
53. Kitagawa, M., Sugiyama, H., Morinaga, H., Inoue, T., Takiue, K., Ogawa, A., Yamanari, T., Kikumoto, Y., Uchida, H.A., Kitamura, S., Maeshima, Y., Nakamura, K., Ito, H., Makino, H., A decreased level of serum soluble Klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One, 8, 2013, e56695.
54. Ko, B., Mistry, A.C., Hanson, L., Mallick, R., Wynne, B.M., Thai, T.L., Bailey, J.L., Klein, J.D., Hoover, R.S., Aldosterone acutely stimulates NCC activity via a SPAK-mediated pathway. Am. J. Physiol. Ren. Physiol. 305 (2013), F645–F652.
55. Komaba, H., Goto, S., Fujii, H., Hamada, Y., Kobayashi, A., Shibuya, K., Tominaga, Y., Otsuki, N., Nibu, K., Nakagawa, K., Tsugawa, N., Okano, T., Kitazawa, R., Fukagawa, M., Kita, T., Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 77 (2010), 232–238.
56. Krajisnik, T., Olauson, H., Mirza, M.A., Hellman, P., Akerstrom, G., Westin, G., Larsson, T.E., Bjorklund, P., Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 78 (2010), 1024–1032.
57. Kuro-o, M., Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat. Rev. Nephrol. 9 (2013), 650–660.
58. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., Iwasaki, H., Iida, A., Shiraki-Iida, T., Nishikawa, S., Nagai, R., Nabeshima, Y.I., Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
59. Kurosu, H., Yamamoto, M., Clark, J.D., Pastor, J.V., Nandi, A., Gurnani, P., McGuinness, O.P., Chikuda, H., Yamaguchi, M., Kawaguchi, H., Shimomura, I., Takayama, Y., Herz, J., Kahn, C.R., Rosenblatt, K.P., Kuro-o, M., Suppression of aging in mice by the hormone Klotho. Science 309 (2005), 1829–1833.
60. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Baum, M.G., Schiavi, S., Hu, M.C., Moe, O.W., Kuro, O., Regulation of fibroblast growth factor-23 signaling by Klotho. J. Biol. Chem. 281 (2006), 6120–6123.
61. Lambers, T.T., Bindels, R.J., Hoenderop, J.G., Coordinated control of renal Ca2+ handling. Kidney Int. 69 (2006), 650–654.
62. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H.S., Juppner, H., Jonsson, K.B., Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 (2004), 3087–3094.
63. Lattanzio, M.R., Weir, M.R., Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?. Curr. Hypertens. Rep. 12 (2010), 369–377.
64. Leifheit-Nestler, M., Grosse, S.R., Flasbart, K., Richter, B., Kirchhoff, F., Ziegler, W.H., Klintschar, M., Becker, J.U., Erbersdobler, A., Aufricht, C., Seeman, T., Fischer, D.C., Faul, C., Haffner, D., Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transpl., 2015 (in press).
65. Li, S.A., Watanabe, M., Yamada, H., Nagai, A., Kinuta, M., Takei, K., Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct. Funct. 29 (2004), 91–99.
66. Li, H., Martin, A., David, V., Quarles, L.D., Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am. J. Physiol. Endocrinol. Metab. 300 (2011), E508–E517.
67. Lim, K., Lu, T.S., Molostvov, G., Lee, C., Lam, F.T., Zehnder, D., Hsiao, L.L., Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125 (2012), 2243–2255.
68. Lindberg, K., Olauson, H., Amin, R., Ponnusamy, A., Goetz, R., Taylor, R.F., Mohammadi, M., Canfield, A., Kublickiene, K., Larsson, T.E., Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One, 8, 2013, e60658.
69. Lindberg, K., Amin, R., Moe, O.W., Hu, M.C., Erben, R.G., Ostman, W.A., Lanske, B., Olauson, H., Larsson, T.E., The kidney is the principal organ mediating klotho effects. J. Am. Soc. Nephrol. 25 (2014), 2169–2175.
70. Martin, A., David, V., Quarles, L.D., Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92 (2012), 131–155.
71. Martuseviciene, G., Hofman-Bang, J., Clausen, T., Olgaard, K., Lewin, E., The secretory response of parathyroid hormone to acute hypocalcemia in vivo is independent of parathyroid glandular sodium/potassium-ATPase activity. Kidney Int. 79 (2011), 742–748.
72. Masso, A., Sanchez, A., Gimenez-Llort, L., Lizcano, J.M., Canete, M., Garcia, B., Torres-Lista, V., Puig, M., Bosch, A., Chillon, M., Secreted and transmembrane alphaklotho isoforms have different spatio-temporal profiles in the brain during aging and Alzheimer's disease progression. PLoS. One, 10, 2015, e0143623.
73. Matsumura, Y., Aizawa, H., Shiraki-Iida, T., Nagai, R., Kuro-o, M., Nabeshima, Y., Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 242 (1998), 626–630.
74. McCormick, J.A., Yang, C.L., Ellison, D.H., WNK kinases and renal sodium transport in health and disease: an integrated view. Hypertension 51 (2008), 588–596.
75. Meir, T., Durlacher, K., Pan, Z., Amir, G., Richards, W.G., Silver, J., Naveh-Many, T., Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 86 (2014), 1106–1115.
76. Mencke, R., Harms, G., Mirkovic, K., Struik, J., Van, A.J., Van, L.E., Verkaik, M., de Borst, M.H., Zeebregts, C.J., Hoenderop, J.G., Vervloet, M.G., Hillebrands, J.L., Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovasc. Res. 108 (2015), 220–231.
77. Miyagawa, K., Yamazaki, M., Kawai, M., Nishino, J., Koshimizu, T., Ohata, Y., Tachikawa, K., Mikuni-Takagaki, Y., Kogo, M., Ozono, K., Michigami, T., Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic Hyp mice. PLoS One, 9, 2014, e93840.
78. Murali, S.K., Roschger, P., Zeitz, U., Klaushofer, K., Andrukhova, O., Erben, R.G., FGF23 regulates bone mineralization in a 1,25(OH) D and klotho-independent manner. J. Bone Min. Res. 31 (2016), 129–142.
79. Myakala, K., Motta, S., Murer, H., Wagner, C.A., Koesters, R., Biber, J., Hernando, N., Renal-specific and inducible depletion of NaPi-IIc/Slc34a3, the cotransporter mutated in HHRH, does not affect phosphate or calcium homeostasis in mice. Am. J. Physiol. Ren. Physiol. 306 (2014), F833–F843.
80. Ohnishi, M., Nakatani, T., Lanske, B., Razzaque, M.S., In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ. Cardiovasc. Genet. 2 (2009), 583–590.
81. Olauson, H., Lindberg, K., Amin, R., Sato, T., Jia, T., Goetz, R., Mohammadi, M., Andersson, G., Lanske, B., Larsson, T.E., Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet., 9, 2013, e1003975.
82. Pathak, J.L., Bakker, A.D., Luyten, F.P., Verschueren, P., Lems, W.F., Klein-Nulend, J., Bravenboer, N., Systemic inflammation affects human osteocyte-specific protein and cytokine expression. Calcif. Tissue Int. 98 (2016), 596–608.
83. Pavik, I., Jaeger, P., Ebner, L., Wagner, C.A., Petzold, K., Spichtig, D., Poster, D., Wuthrich, R.P., Russmann, S., Serra, A.L., Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol. Dial. Transpl. 28 (2013), 352–359.
84. Quinn, S.J., Thomsen, A.R., Pang, J.L., Kantham, L., Brauner-Osborne, H., Pollak, M., Goltzman, D., Brown, E.M., Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am. J. Physiol. Endocrinol. Metab. 304 (2013), E310–E320.
85. Rozansky, D.J., Cornwall, T., Subramanya, A.R., Rogers, S., Yang, Y.F., David, L.L., Zhu, X., Yang, C.L., Ellison, D.H., Aldosterone mediates activation of the thiazide-sensitive Na-Cl cotransporter through an SGK1 and WNK4 signaling pathway. J. Clin. Invest 119 (2009), 2601–2612.
86. Scialla, J.J., Lau, W.L., Reilly, M.P., Isakova, T., Yang, H.Y., Crouthamel, M.H., Chavkin, N.W., Rahman, M., Wahl, P., Amaral, A.P., Hamano, T., Master, S.R., Nessel, L., Chai, B., Xie, D., Kallem, R.R., Chen, J., Lash, J.P., Kusek, J.W., Budoff, M.J., Giachelli, C.M., Wolf, M., Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 83 (2013), 1159–1168.
87. Scialla, J.J., Xie, H., Rahman, M., Anderson, A.H., Isakova, T., Ojo, A., Zhang, X., Nessel, L., Hamano, T., Grunwald, J.E., Raj, D.S., Yang, W., He, J., Lash, J.P., Go, A.S., Kusek, J.W., Feldman, H., Wolf, M., Fibroblast growth factor-23 and cardiovascular events in CKD. J. Am. Soc. Nephrol. 25 (2014), 349–360.
88. Seiler, S., Rogacev, K.S., Roth, H.J., Shafein, P., Emrich, I., Neuhaus, S., Floege, J., Fliser, D., Heine, G.H., Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin. J. Am. Soc. Nephrol. 9 (2014), 1049–1058.
89. Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., Yamashita, T., Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 6500–6505.
90. Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., Yamashita, T., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Min. Res. 19 (2004), 429–435.
91. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K., Yamashita, T., Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest 113 (2004), 561–568.
92. Shimada, T., Urakawa, I., Yamazaki, Y., Hasegawa, H., Hino, R., Yoneya, T., Takeuchi, Y., Fujita, T., Fukumoto, S., Yamashita, T., FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004), 409–414.
93. Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., Fukumoto, S., Yamashita, T., Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Ren. Physiol. 289 (2005), F1088–F1095.
94. Shiraki-Iida, T., Aizawa, H., Matsumura, Y., Sekine, S., Iida, A., Anazawa, H., Nagai, R., Kuro-o, M., Nabeshima, Y., Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 424 (1998), 6–10.
95. Silswal, N., Touchberry, C.D., Daniel, D.R., McCarthy, D.L., Zhang, S., Andresen, J., Stubbs, J.R., Wacker, M.J., FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 307 (2014), E426–E436.
96. Sitara, D., Razzaque, M.S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R.G., Juppner, H., Lanske, B., Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004), 421–432.
97. Streicher, C., Zeitz, U., Andrukhova, O., Rupprecht, A., Pohl, E., Larsson, T.E., Windisch, W., Lanske, B., Erben, R.G., Long-term Fgf23 deficiency does not influence aging, glucose homeostasis, or fat metabolism in mice with a nonfunctioning vitamin D receptor. Endocrinology 153 (2012), 1795–1805.
98. Stubbs, J.R., Liu, S., Tang, W., Zhou, J., Wang, Y., Yao, X., Quarles, L.D., Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J. Am. Soc. Nephrol. 18 (2007), 2116–2124.
99. Tagliabracci, V.S., Engel, J.L., Wiley, S.E., Xiao, J., Gonzalez, D.J., Nidumanda, A.H., Koller, A., Nizet, V., White, K.E., Dixon, J.E., Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 5520–5525.
100. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000), 345–348.
101. Tohyama, O., Imura, A., Iwano, A., Freund, J.N., Henrissat, B., Fujimori, T., Nabeshima, Y., Klotho is a novel beta-glucuronidase capable of hydrolyzing steroid beta-glucuronides. J. Biol. Chem. 279 (2004), 9777–9784.
102. Topaz, O., Shurman, D.L., Bergman, R., Indelman, M., Ratajczak, P., Mizrachi, M., Khamaysi, Z., Behar, D., Petronius, D., Friedman, V., Zelikovic, I., Raimer, S., Metzker, A., Richard, G., Sprecher, E., Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36 (2004), 579–581.
103. Umbach, A.T., Zhang, B., Daniel, C., Fajol, A., Velic, A., Hosseinzadeh, Z., Bhavsar, S.K., Bock, C.T., Kandolf, R., Pichler, B.J., Amann, K.U., Foller, M., Lang, F., Janus kinase 3 regulates renal 25-hydroxyvitamin D 1alpha-hydroxylase expression, calcitriol formation, and phosphate metabolism. Kidney Int. 87 (2015), 728–737.
104. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., Yamashita, T., Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
105. van der Lubbe, N., Lim, C.H., Meima, M.E., van, V.R., Rosenbaek, L.L., Mutig, K., Danser, A.H., Fenton, R.A., Zietse, R., Hoorn, E.J., Aldosterone does not require angiotensin II to activate NCC through a WNK4-SPAK-dependent pathway. Pflugers Arch. 463 (2012), 853–863.
106. Wang, X., Wang, S., Li, C., Gao, T., Liu, Y., Rangiani, A., Sun, Y., Hao, J., George, A., Lu, Y., Groppe, J., Yuan, B., Feng, J.Q., Qin, C., Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet., 8, 2012, e1002708.
107. Weinman, E.J., Biswas, R.S., Peng, G., Shen, L., Turner, C.L., E X, Steplock, D., Shenolikar, S., Cunningham, R., Parathyroid hormone inhibits renal phosphate transport by phosphorylation of serine 77 of sodium-hydrogen exchanger regulatory factor-1. J. Clin. Invest 117 (2007), 3412–3420.
108. Weinman, E.J., Steplock, D., Shenolikar, S., Biswas, R., FGF-23-mediated inhibition of renal phosphate transport in mice requires NHERF-1 and synergizes with PTH. J. Biol. Chem. 286 (2011), 37216–37221.
109. White, K.E., Econs, M.J., Fibroblast growth Factor-23. Rosen, C.J., (eds.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 2008, American Society of Bone and Mineral Research, Washington, DC, 112–116.
110. White, K.E., Cabral, J.M., Davis, S.I., Fishburn, T., Evans, W.E., Ichikawa, S., Fields, J., Yu, X., Shaw, N.J., McLellan, N.J., McKeown, C., Fitzpatrick, D., Yu, K., Ornitz, D.M., Econs, M.J., Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am. J. Hum. Genet. 76 (2005), 361–367.
111. Witteveen, J.E., van Lierop, A.H., Papapoulos, S.E., Hamdy, N.A., Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?. Eur. J. Endocrinol. 166 (2012), 55–60.
112. Wolf, M., White, K.E., Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 23 (2014), 411–419.
113. Wolf, M.T., An, S.W., Nie, M., Bal, M.S., Huang, C.L., Klotho up-regulates renal calcium channel transient receptor potential vanilloid 5 (TRPV5) by intra- and extracellular N-glycosylation-dependent mechanisms. J. Biol. Chem. 289 (2014), 35849–35857.
114. Xiao, Z., Huang, J., Cao, L., Liang, Y., Han, X., Quarles, L.D., Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS One, 9, 2014, e104154.
115. Xie, J., Cha, S.K., An, S.W., Kuro, O., Birnbaumer, L., Huang, C.L., Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat. Commun., 3, 2012, 1238.
116. Xu, Y., Sun, Z., Molecular basis of Klotho: from gene to function in aging. Endocr. Rev. 36 (2015), 174–193.
117. Yamashita, T., Yoshioka, M., Itoh, N., Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 277 (2000), 494–498.
118. Yokoyama, J.S., Sturm, V.E., Bonham, L.W., Klein, E., Arfanakis, K., Yu, L., Coppola, G., Kramer, J.H., Bennett, D.A., Miller, B.L., Dubal, D.B., Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann. Clin. Transl. Neurol. 2 (2015), 215–230.
119. Yoshiko, Y., Wang, H., Minamizaki, T., Ijuin, C., Yamamoto, R., Suemune, S., Kozai, K., Tanne, K., Aubin, J.E., Maeda, N., Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007), 1565–1573.
120. Yuan, Q., Sato, T., Densmore, M., Saito, H., Schuler, C., Erben, R.G., Lanske, B., Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice. PLoS Genet., 8, 2012, e1002726.
121. Yuan, Q., Jiang, Y., Zhao, X., Sato, T., Densmore, M., Schuler, C., Erben, R.G., McKee, M.D., Lanske, B., Increased osteopontin contributes to inhibition of bone mineralization in FGF23-deficient mice. J. Bone Min. Res. 29 (2014), 693–704.